Journal Mobile Options
Table of Contents
Vol. 39, No. 2, 2001
Issue release date: February 2001
Section title: BPH
Eur Urol 2001;39:151–158
(DOI:10.1159/000052430)

Hyperinsulinaemia as a Risk Factor for Developing Benign Prostatic Hyperplasia

Hammarsten J.a · Högstedt B.b
aUrological Section, Department of Surgery, Varberg Hospital, Varberg, and bDepartment of Occupational Medicine, Central Hospital, Halmstad, Sweden; Source of funding: Scientific Council, County of Halland.

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

For eJournal Archive and eJournal Backfiles information please contact service@karger.com


Article / Publication Details

First-Page Preview
Abstract of BPH

Published online: 2/8/2001
Issue release date: February 2001

Number of Print Pages: 8
Number of Figures: 1
Number of Tables: 3

ISSN: 0302-2838 (Print)
eISSN: 1421-993X (Online)

For additional information: http://www.karger.com/EUR

Abstract

Objective: To determine the validity coefficient of the total prostate gland volume as an expression of the transition zone (TZ) volume. To test the hypothesis of hyperinsulinaemia as a causal factor for the development of benign prostatic hyperplasia (BPH). Patients and Methods: Three hundred and seven consecutive patients with lower urinary tract symptoms were studied. A subgroup of 114 patients were tested with regard to the validity coefficient between the total prostate gland volume and the TZ volume. In the total material of 307 men, a BPH risk factor analysis was performed in which groups of men with the following conditions were related to the annual BPH growth rate: men without or with metabolic disease; men with different components of the metabolic syndrome, and men with low or high fasting plasma insulin values. The prostate gland volume and the TZ volume were determined using ultrasound. The presence of non–insulin–dependent diabetes mellitus (NIDDM) and treated hypertension was obtained from the patients’ medical records. Data on blood pressure, waist and hip measurement, body height and weight were collected and body mass index and waist/hip ratio were calculated. Blood samples were drawn from fasting patients to determine the insulin and HDL–cholesterol values. Results: In the subgroup of men subjected to measurement of both the total prostate gland volume and the TZ volume, the correlation coefficient between total prostate gland volume and the TZ volume was r.s. =0.97 (p<0.0001) which, thus, constituted the validity coefficient. The median annual BPH growth rate in the total group was 1.03 ml/year. The median annual BPH growth rate was faster in men with metabolic disease (p<0.0001), NIDDM (p<0.0001), treated hypertension (p<0.0001), obesity (p<0.0001) and dyslipidaemia (p<0.0001) than in men without metabolic disease. Moreover, the annual BPH growth rate correlated positively with the diastolic blood pressure (r.s. = 0.27; p<0.001), the BMI (r.s. = 0.22; p<0.001) and four other expressions of obesity, and negatively with the HDL–cholesterol level (r.s. = –0.15; p<0.001). The median annual BPH growth rate was faster in men with a high than in men with a low fasting plasma insulin level (p = 0.019). When the patients were divided into quartiles, the median annual BPH growth rate increased statistically significantly with increasing fasting plasma insulin levels. The fasting plasma insulin values correlated with the annual BPH growth rates (p = 0.009). When performing a multivariate analysis using the total prostate gland volume as dependent variable, fasting plasma insulin (p = 0.001) and age (p<0.001) became statistically significant. Conclusion: The results of the present report suggest that the total prostate gland volume constitutes a valid expression of BPH. The findings support the hypothesis that hyperinsulinaemia is causally related to the development of BPH and generate the hypothesis of an increased sympathetic nerve activity in men with BPH.


  

Author Contacts

Dr. Jan Hammarsten
Department of Surgery, Varberg Hospital
S–432 81 Varberg (Sweden)
Tel. +46 340 81000, Fax +46 340 84437
E–Mail jan.hammarsten@lthalland.se

  

Article Information

Accepted after revision: August 30, 2000
Number of Print Pages : 8
Number of Figures : 1, Number of Tables : 3, Number of References : 58

  

Publication Details

European Urology
Official Organ of the European Association of Urology

Vol. 39, No. 2, Year 2001 (Cover Date: February 2001)

Journal Editor: C.C. Schulman, Brussels
ISSN: 0302–2838 (print), 1421–993X (Online)

For additional information: http://www.karger.ch/journals/eur


Article / Publication Details

First-Page Preview
Abstract of BPH

Published online: 2/8/2001
Issue release date: February 2001

Number of Print Pages: 8
Number of Figures: 1
Number of Tables: 3

ISSN: 0302-2838 (Print)
eISSN: 1421-993X (Online)

For additional information: http://www.karger.com/EUR


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.